Get in touch with the latest research developments at the Radboudumc. The weekly Radboud Research Rounds focus on the ambitions of the newly formed research themes, and illustrate how personalized healthcare is being embodied in the research strategy.

In a new format of presentations investigators provide insight in the strengths of each research theme. With room for interactive discussions to increase focus and synergism. Continue discussions afterwards with light refreshments in the Radboud Research Café.

The Radboud Research Rounds, open to everyone, are an excellent opportunity to get involved in your own research theme and to learn more from other themes. The Radboud Research Rounds are organized by the Radboud Institute for Health Sciences, Radboud Institute for Molecular Life Sciences and the Donders Centre for Neurosciences.

Dr. Gerhardt Attard specialises in the development of drugs and biomarkers for prostate cancer, working at both the laboratory and clinical trials stages.

Dr. Attard was awarded a Cancer Research UK Clinician Scientist Fellowship in 2012 and also receives research funding from the European Union Marie Curie funding programme, Prostate Cancer UK, the Prostate Cancer Foundation (Santa Monica, California) and Movember.

Dr. Attard is an associate editor with the journal Annals of Oncology and sits on the scientific advisory boards of several companies. He has published over 90 peer-reviewed manuscripts and received awards for his work on abiraterone from several institutions including the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the UK Association of Cancer Physicians, the Prostate Cancer Foundation and the Medical Research Society and Academy of Medical Sciences.

Dr. Attard specialises in castration-resistant prostate cancer and drug development. His research focuses on reversing resistance to endocrine treatment in prostate cancer and developing circulating biomarkers to molecularly characterise advanced cancer patients. The group is currently working on projects looking at circulating plasma nucleic acids (funded by Prostate Cancer UK and the Prostate Cancer Foundation) and circulating tumour cells (funded by Movember). Dr Attard is also principal investigator for several clinical trials evaluating new strategies for targeting steroid receptor signalling in castration-resistant prostate cancer.